Treatment Response and Adverse Reactions in Older Tuberculosis Patients with Immunocompromising Comorbidities

PURPOSE: The aim of this study was to elucidate the effects of immunocompromising comorbidities on treatment response and adverse reactions in older tuberculosis (TB) patients. MATERIALS AND METHODS: The medical records of 182 patients older than 65 years with proven TB by positive culture of Mycoba...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Seo Yun, Lee, Sang-Min, Yim, Jae-Joon, Yoo, Chul-Gyu, Kim, Young Whan, Han, Sung Koo, Yang, Seok-Chul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Yonsei University College of Medicine 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3743193/
https://www.ncbi.nlm.nih.gov/pubmed/23918574
http://dx.doi.org/10.3349/ymj.2013.54.5.1227
_version_ 1782280460809797632
author Kim, Seo Yun
Lee, Sang-Min
Yim, Jae-Joon
Yoo, Chul-Gyu
Kim, Young Whan
Han, Sung Koo
Yang, Seok-Chul
author_facet Kim, Seo Yun
Lee, Sang-Min
Yim, Jae-Joon
Yoo, Chul-Gyu
Kim, Young Whan
Han, Sung Koo
Yang, Seok-Chul
author_sort Kim, Seo Yun
collection PubMed
description PURPOSE: The aim of this study was to elucidate the effects of immunocompromising comorbidities on treatment response and adverse reactions in older tuberculosis (TB) patients. MATERIALS AND METHODS: The medical records of 182 patients older than 65 years with proven TB by positive culture of Mycobacterium tuberculosis and with available drug susceptibility tests were reviewed retrospectively. These patients were subsequently assigned to either the comorbidity group (n=78) or non-comorbidity group (n=104) depending on whether they had immunocompromising comorbidities. RESULTS: The mean durations of treatment were 9.9±3.3 months in the comorbidity group and 9.3±3.2 months in the non-comorbidity group (p=0.21). M. tuberculosis culture results converted to negative in most patients with available follow-up cultures at two months after treatment. The successful treatment rates were 94.9% and 98.9% in the comorbidity and non-comorbidity groups, respectively (p=0.30). The most common side effects of anti-TB treatment were skin rash/pruritus (13% in the comorbidity group vs. 11% in the non-comorbidity group, p=0.79), gastro-intestinal problems (14% vs. 9%, p=0.25) and hepatotoxicity (14% vs. 7%, p=0.09). CONCLUSION: The present study shows that the successful treatment rate for TB is high and that immunocompromising comorbidities have no effect on the response to treatment and adverse effects in older TB patients.
format Online
Article
Text
id pubmed-3743193
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Yonsei University College of Medicine
record_format MEDLINE/PubMed
spelling pubmed-37431932013-09-01 Treatment Response and Adverse Reactions in Older Tuberculosis Patients with Immunocompromising Comorbidities Kim, Seo Yun Lee, Sang-Min Yim, Jae-Joon Yoo, Chul-Gyu Kim, Young Whan Han, Sung Koo Yang, Seok-Chul Yonsei Med J Original Article PURPOSE: The aim of this study was to elucidate the effects of immunocompromising comorbidities on treatment response and adverse reactions in older tuberculosis (TB) patients. MATERIALS AND METHODS: The medical records of 182 patients older than 65 years with proven TB by positive culture of Mycobacterium tuberculosis and with available drug susceptibility tests were reviewed retrospectively. These patients were subsequently assigned to either the comorbidity group (n=78) or non-comorbidity group (n=104) depending on whether they had immunocompromising comorbidities. RESULTS: The mean durations of treatment were 9.9±3.3 months in the comorbidity group and 9.3±3.2 months in the non-comorbidity group (p=0.21). M. tuberculosis culture results converted to negative in most patients with available follow-up cultures at two months after treatment. The successful treatment rates were 94.9% and 98.9% in the comorbidity and non-comorbidity groups, respectively (p=0.30). The most common side effects of anti-TB treatment were skin rash/pruritus (13% in the comorbidity group vs. 11% in the non-comorbidity group, p=0.79), gastro-intestinal problems (14% vs. 9%, p=0.25) and hepatotoxicity (14% vs. 7%, p=0.09). CONCLUSION: The present study shows that the successful treatment rate for TB is high and that immunocompromising comorbidities have no effect on the response to treatment and adverse effects in older TB patients. Yonsei University College of Medicine 2013-09-01 2013-07-23 /pmc/articles/PMC3743193/ /pubmed/23918574 http://dx.doi.org/10.3349/ymj.2013.54.5.1227 Text en © Copyright: Yonsei University College of Medicine 2013 http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Kim, Seo Yun
Lee, Sang-Min
Yim, Jae-Joon
Yoo, Chul-Gyu
Kim, Young Whan
Han, Sung Koo
Yang, Seok-Chul
Treatment Response and Adverse Reactions in Older Tuberculosis Patients with Immunocompromising Comorbidities
title Treatment Response and Adverse Reactions in Older Tuberculosis Patients with Immunocompromising Comorbidities
title_full Treatment Response and Adverse Reactions in Older Tuberculosis Patients with Immunocompromising Comorbidities
title_fullStr Treatment Response and Adverse Reactions in Older Tuberculosis Patients with Immunocompromising Comorbidities
title_full_unstemmed Treatment Response and Adverse Reactions in Older Tuberculosis Patients with Immunocompromising Comorbidities
title_short Treatment Response and Adverse Reactions in Older Tuberculosis Patients with Immunocompromising Comorbidities
title_sort treatment response and adverse reactions in older tuberculosis patients with immunocompromising comorbidities
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3743193/
https://www.ncbi.nlm.nih.gov/pubmed/23918574
http://dx.doi.org/10.3349/ymj.2013.54.5.1227
work_keys_str_mv AT kimseoyun treatmentresponseandadversereactionsinoldertuberculosispatientswithimmunocompromisingcomorbidities
AT leesangmin treatmentresponseandadversereactionsinoldertuberculosispatientswithimmunocompromisingcomorbidities
AT yimjaejoon treatmentresponseandadversereactionsinoldertuberculosispatientswithimmunocompromisingcomorbidities
AT yoochulgyu treatmentresponseandadversereactionsinoldertuberculosispatientswithimmunocompromisingcomorbidities
AT kimyoungwhan treatmentresponseandadversereactionsinoldertuberculosispatientswithimmunocompromisingcomorbidities
AT hansungkoo treatmentresponseandadversereactionsinoldertuberculosispatientswithimmunocompromisingcomorbidities
AT yangseokchul treatmentresponseandadversereactionsinoldertuberculosispatientswithimmunocompromisingcomorbidities